Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

• Status: Terminated
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost

Criteria

Inclusion Criteria:

• Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year

Exclusion Criteria:

• History of Paget's disease, osteoporosis, or bone malignancy

• History of bone fracture within the previous 12 months, except for metatarsal, metacarpal, or skull fractures

• Patient is currently undergoing radiation therapy or anticipates undergoing radiation therapy at any time during the study

• Drug or alcohol abuse within 12 months

• HIV positive

• Received hair transplants or had scalp reductions

• Use of hair weaves, hair extensions or wigs within 3 months

• Application of topical medications, minoxidil or nonsteroidal anti-inflammatory drugs (NSAIDs) to scalp within 4 weeks